Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
Ulrich Pecks, Head of Obstetrics and Maternal Health and Fetal Development at University Hospital Würzburg, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“In addition to our recent publication on VTE prophylaxis after CS in JPM we are proud of our accepted review in Archives which provides an overview of guidelines for hereditary thrombophilia in pregnancy.
Key points:
- Pregnant women with inherited thrombophilia have a significantly higher risk of venous thromboembolism (VTE), up to approximately 40-fold depending on type and history.
Risk classification:
- Low risk: e.g., heterozygous factor V Leiden or prothrombin mutation
- High risk: e.g., homozygous mutations, combined thrombophilia, severe antithrombin/protein C/S deficiency
Guidelines vary:
International recommendations for thromboprophylaxis differ widely – no universal standard.
Use of prophylaxis (heparin):
Generally recommended for high-risk thrombophilia (during pregnancy and 6 weeks postpartum).
For low-risk, only if additional risk factors or positive family history are present.
Limited evidence:
There is no strong evidence from randomized controlled trials proving that pharmacological prophylaxis significantly reduces VTE risk.
Risk–benefit balance:
Prophylaxis carries risks (e.g., bleeding), and VTE risk may be overestimated – possible overtreatment.
Individualized decision-making:
Management should be case-by-case, considering individual risk profile, history, and patient preference.
Bottom line:
Although VTE risk is increased in pregnant women with thrombophilia, inconsistent guidelines and limited evidence mean that prophylaxis decisions must be individualized.”
Title: Recommendations from guidelines for the prevention of venous thromboembolism in pregnant women with inherited thrombophilia
Authors: Werner Rath, Panagiotis Tsikouras, Ulrich Pecks
Read the Full Article on Archives of Gynecology and Obstetrics.
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 31, 2026, 17:11Chokri Ben Lamine: Early Recognition and Immediate Treatment of Catastrophic APS
-
Aug 31, 2026, 17:06Nikolaos Ktenopoulos: COMPASS-ARTeCAT Trial Highlights Arterial Thrombosis in Patients With Cancer
-
Aug 31, 2026, 17:01Mark Kaplan: Same LDL-C, Different Coagulation, Different Outcomes, in FH
-
Aug 31, 2026, 16:55Kemal Karaagac: Milvexian Did Not Reduce Ischemic Events but Did Not Increase Fatal Bleeding
-
Aug 31, 2026, 16:47Improving Outcomes in AF-Related Stroke Beyond Anticoagulation at ESC 2026 – ESO
-
Aug 31, 2026, 16:39Shariq Shamim: Are We Going to Start DOAC post TAVI not DAPT?
-
Aug 31, 2026, 16:30Bartosz Hudzik: 5th Universal MI Definition Moves Closer to Biology in Women
-
Aug 31, 2026, 16:13Seema Dawood: Nucleated Red Blood Cells – What They Tell Us on a Peripheral Smear
-
Aug 31, 2026, 16:02Antonio Sorropago: Major Updates in Structural Heart Interventions